STAA STAAR SURGICAL CO
Ophthalmic Goods · Nasdaq · SEC CIK 718937 · Fiscal year ends 01/02
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.4%
TTM net income YoY100.5%
TTM EPS YoY100.5%
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR-69.9%
Margins
Gross margin73.6%
Operating margin0.2%
Net margin0.2%
FCF margin5.4%
EBITDA margin2.9%
Returns
ROE0.1%
ROA0.1%
ROIC (approx.)0.2%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets22.5%
Debt / equity0.00x
Current ratio4.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income40.37x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-02 | FY20242024-12-27 | FY20232023-12-29 | FY20222022-12-30 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $239.44M | $313.90M | $322.42M | $239.44M | $230.47M |
| Cost of revenue | $57.02M | $74.32M | $69.76M | $61.01M | $51.84M |
| Gross profit | $182.42M | $239.58M | $252.65M | $223.38M | $178.64M |
| R&D expense | $40.05M | $45.32M | $40.48M | $35.98M | $33.86M |
| SG&A expense | $274.13M | $252.19M | $224.55M | $179.58M | $145.30M |
| Operating income | -$91.71M | -$12.61M | $28.10M | $43.80M | $33.34M |
| Pretax income | -$82.26M | -$9.05M | $33.70M | $45.55M | $31.30M |
| Income tax | -$1.81M | $11.16M | $12.35M | $5.89M | $3.79M |
| Net income | -$80.45M | -$20.21M | $21.35M | $39.66M | $27.51M |
| EBITDA | -$83.39M | -$5.72M | $33.21M | $48.28M | $36.95M |
| EPS (basic) | -1.62 | -0.41 | 0.44 | 0.83 | 0.58 |
| EPS (diluted) | -1.62 | -0.41 | 0.43 | 0.80 | 0.56 |
| Weighted avg. shares (diluted) | 49.57M | 49.12M | 49.43M | 49.38M | 49.46M |
| Balance sheet | |||||
| Cash & equivalents | $153.15M | $144.16M | $183.04M | $86.48M | $199.71M |
| Short-term investments | $34.39M | $86.33M | $37.69M | $125.16M | — |
| Receivables | $50.06M | $77.90M | $94.70M | $62.45M | $43.53M |
| Inventory | $58.42M | $44.58M | $38.64M | $25.84M | $18.43M |
| Current assets | $311.55M | $367.94M | $365.27M | $311.72M | $271.41M |
| PP&E, net | $73.32M | $84.89M | $66.83M | $50.92M | $35.91M |
| Goodwill | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M |
| Intangibles | — | — | — | $173,000 | $218,000 |
| Total assets | $451.68M | $509.52M | $488.69M | $418.82M | $345.78M |
| Current liabilities | $68.50M | $70.31M | $65.04M | $51.72M | $48.80M |
| Total liabilities | $107.49M | $112.19M | $102.74M | $82.71M | $87.22M |
| Shareholders' equity | $344.18M | $397.33M | $385.95M | $336.11M | $261.57M |
| Shares outstanding | 49.40M | 49.29M | 48.84M | 48.21M | 47.72M |
| Cash flow statement | |||||
| Operating cash flow | -$34.23M | $15.72M | $14.59M | $35.72M | $43.96M |
| Capital expenditure | $5.82M | $23.39M | $18.19M | $18.11M | $13.64M |
| Free cash flow | -$40.05M | -$7.67M | -$3.59M | $17.61M | $30.32M |
| Investing cash flow | $46.34M | -$59.22M | $74.35M | -$156.38M | -$13.64M |
| Financing cash flow | -$4.55M | $5.72M | $7.42M | $8.30M | $17.79M |
| Depreciation & amortization | $8.32M | $6.89M | $5.11M | $4.48M | $3.61M |
| Stock-based compensation | $30.59M | $27.21M | $23.52M | $20.37M | $14.61M |
| Share buybacks | $6.46M | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.